Newsroom
Latest Press Release
Latest News
| January 02, 2013 | | Julianna Lisziewicz, president and CEO of the Genetic Immunity, was interviewed on the VLP meeting in November in Cannes
Julianna Lisziewicz, president and CEO of the
company Genetic Immunity, presented a therapeutic
vaccine approach that’s based on synthetic
nanoparticles and intended to induce an immune
response that kills infected cells in HIV-infected
individuals. The immunotherapy, as Lisziewicz
calls it, is named DermaVir and consists of synthetic
nanoparticles with diameters between 70 nm to
300 nm. Each carries a single plasmid DNA inside
that encodes all 15 HIV proteins, two of which are
nonfunctional to ensure that the resulting HIV particles
cannot integrate or replicate (Vaccine 29, 744,
2011). This, Lisziewicz said, makes DermaVir the
most complete vaccine modality in terms of the
number of HIV epitopes used.
Before DermaVir is used, a rough sponge is
rubbed over the application site to disrupt the outermost
epidermal layer (stratum corneum). Then
the skin area is covered for three hours with about
1013 nanoparticles, which are applied as a liquid
and contained by a patch. To improve the immune
response, the patches are applied at different locations,
so that responses are simultaneously activated
inside a number of different lymph nodes.
Lisziewicz said data from mice, rabbits and
monkeys show that some of the particles are
taken up by Langerhans cells, the antigen presenting
cells (APCs) of the skin. They then carry
the particles with them as they migrate to lymph
nodes, mature into DCs and express the HIV
genes from the nanoparticles. The resulting HIV
VLPs contain all HIV proteins but cannot integrate
into the genome or replicate. For further information please see the full article (page 7).
| | | | September 28, 2012 | | Amerikai Tőzsdén a Genetic Immunity
Power of the Dream Ventures, Inc. (PWRV), és a Genetic Immunity Inc. örömmel jelenti be, hogy mostantól a részvényeik együtt forognak az OTC BB tőzsde piacán. A Genetic Immunity személyre szabott immunterápiákat fejleszt, amelyek piacát 2018-ra mintegy 11 milliárd USD-ra becsülik a szakértők.
A teljes cikket PDF formátumbanletölthetik innnen.
| | | | August 20, 2012 | | Topol on The Creative Destruction of Medicine
Dr. Eric Topol tries to get into critical aspects of how they can Schumpeter or reboot the future of healthcare by leveraging the big innovations that are occurring in the digital world, including digital medicine. For the full article please follow this link to Medscape.
| | | | See More News... |
| |
|
